A 38-year-old woman with severe community-acquired pneumonia is admitted to the ICU. On day 4 of hospitalization, she develops progressive hypoxemia despite antibiotics and supplemental oxygen. Chest X-ray shows new bilateral infiltrates. PaO₂ is 58 mmHg on FiO₂ 0.8, PaCO₂ is 38 mmHg, and PAWP is 12 mmHg. She is intubated and placed on mechanical ventilation. After 48 hours of lung-protective ventilation, her PaO₂/FiO₂ ratio remains 72 (severe ARDS). Which of the following interventions is most strongly supported by evidence to improve oxygenation and potentially reduce mortality?

Explanation

## Diagnosis: Severe ARDS with Refractory Hypoxemia This patient has: - Severe ARDS (PaO₂/FiO₂ = 72, <100) - Bilateral infiltrates consistent with ARDS - Normal PAWP (12 mmHg) excluding cardiogenic pulmonary edema - Failure to improve with standard lung-protective ventilation ## Evidence-Based Rescue Therapies for Severe ARDS ### Prone Positioning: The Gold Standard **High-Yield:** The PROSEVA trial (2013) demonstrated that prone positioning for ≥16 hours daily in severe ARDS (PaO₂/FiO₂ <100) reduces 28-day mortality from 32.8% to 16.0% (absolute risk reduction ~17%). **Key Point:** Prone positioning works by: 1. Redistributing ventilation to dorsal lung regions (better perfusion) 2. Reducing ventral alveolar overdistension 3. Improving secretion drainage 4. Decreasing ventilator-induced lung injury **Clinical Pearl:** Prone positioning is most effective when: - Initiated early (within 36 hours of ARDS onset is ideal, but benefit seen up to day 10) - Applied for ≥16 hours per day - Combined with lung-protective ventilation - Used in severe ARDS (PaO₂/FiO₂ <100) **Mnemonic: PRONE Benefits = "DOSED"** - **D**orsal redistribution of ventilation - **O**verdistension reduction - **S**ecretion drainage - **E**arly mortality reduction - **D**uration ≥16 hours daily ### Comparison of Rescue Therapies | Intervention | Evidence | Mortality Benefit | Timing | |---|---|---|---| | **Prone positioning** | PROSEVA (2013) | Yes (~16% mortality reduction) | Early, severe ARDS | | **Inhaled nitric oxide (iNO)** | Multiple RCTs | No mortality benefit; improves oxygenation transiently | Not recommended as monotherapy | | **ECMO** | CESAR (2009), EOLIA (2018) | Potential benefit in refractory hypoxemia; requires specialized centers | Last resort after all other measures | | **High PEEP strategy** | ALVEOLI trial | No mortality benefit; risk of barotrauma if plateau >30 cm H₂O | Avoid excessive PEEP | ## Management Algorithm for This Patient ```mermaid flowchart TD A[Severe ARDS<br/>PaO2/FiO2 < 100]:::outcome --> B[Lung-protective ventilation<br/>6-8 mL/kg, PEEP titration]:::action B --> C{Refractory hypoxemia<br/>after 48 hours?}:::decision C -->|Yes| D[Prone positioning<br/>≥16 hours daily]:::action D --> E{Response?}:::decision E -->|Improved| F[Continue prone positioning<br/>+ standard care]:::action E -->|No improvement<br/>after 5-7 days| G[Consider iNO or ECMO<br/>at specialized center]:::urgent C -->|No| H[Continue standard therapy<br/>Reassess daily]:::action ```